![Markus Hecker](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Markus Hecker
Corporate Officer/Principal bij Ruprecht-Karls-Universität Heidelberg
Profiel
Markus Hecker is the founder of Avontec GmbH, which was founded in 2001.
He held the title of Director-Supervisory Board from 2009 to 2010.
Dr. Hecker is currently working at Ruprecht-Karls-Universität Heidelberg as Director-Physiology & Pathophysiology since 2009.
Dr. Hecker has previously worked at the University of Freiburg, St. Bartholomew's Hospital, and Georgetown University as a Principal.
From 1996 to 2004, he worked at the University of Gottingen as a Principal.
Dr. Hecker obtained his doctorate degree from Universität Konstanz.
Actieve functies van Markus Hecker
Bedrijven | Functie | Begin |
---|---|---|
Ruprecht-Karls-Universität Heidelberg | Corporate Officer/Principal | 05-11-2009 |
Eerdere bekende functies van Markus Hecker
Bedrijven | Functie | Einde |
---|---|---|
Avontec GmbH
![]() Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Oprichter | 16-06-2010 |
University of Gottingen | Corporate Officer/Principal | 01-01-2004 |
University of Freiburg | Corporate Officer/Principal | - |
St. Bartholomew's Hospital | Corporate Officer/Principal | - |
Georgetown University | Corporate Officer/Principal | - |
Opleiding van Markus Hecker
Universität Konstanz | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Avontec GmbH
![]() Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Health Technology |
St. Bartholomew's Hospital |